Allogeneic NK cell injection / BOE Technology Group - LARVOL DELTA

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd. | Initiation date: May 2026 ➔ Aug 2026

Trial initiation date • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • HER-2 • KRAS • ROS1

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd.

New P1/2 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • HER-2 • KRAS • ROS1

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd. | N=20 ➔ 42

Enrollment change • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • HER-2 • KRAS • ROS1

NK Cell Injection for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd.

New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor